U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H18BrClN4O2.ClH
Molecular Weight 486.19
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PAROGRELIL HYDROCHLORIDE

SMILES

Cl.ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1

InChI

InChIKey=QWGUGDYWUADMGB-UHFFFAOYSA-N
InChI=1S/C19H18BrClN4O2.ClH/c20-16-17(23-12-14-3-1-9-22-11-14)19(25-24-18(16)26)27-10-2-4-13-5-7-15(21)8-6-13;/h1,3,5-9,11H,2,4,10,12H2,(H2,23,24,26);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C19H18BrClN4O2
Molecular Weight 449.729
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19616537

NT-702 (parogrelil hydrochloride) is a novel phosphodiesterase 3 (PDE) inhibitor, and being developed for the treatment of intermittent claudication (IC) in patients with peripheral arterial disease. In Japan, Phase 2 studies are being conducted for intermittent claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis, and asthma. In the USA, a Phase 2 study for intermittent claudication caused by arteriosclerosis obliterans has been successfully completed. Also was shown, that NT-702 has an anti-inflammatory effect as well as a bronchodilating effect and might be useful as a novel potent therapeutic agent with both a bronchodilating and an anti-inflammatory effect.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase 3 inhibitor, suppress the asthmatic response in guinea pigs, with both bronchodilating and anti-inflammatory effects.
2009 Sep 15
Patents

Sample Use Guides

4 mg and/or 8 mg PAROGRELIL taken twice a day for 24 weeks
Route of Administration: Oral
Was investigated the effects of NT-702 (PAROGRELIL) on arterioles isolated from rabbit lumbar spinal cords. NT-702 caused a dose-dependent dilation of the isolated spinal arterioles. The disruption of endothelium produced a significant reduction of higher concentrations(10(-7) and 10(-6) M), but not lower concentrations (less than 10(-8) M), of NT-702-induced vasodilation. The NT-702-induced vasodilation of the arterioles with endothelium was not affected by pretreatment with an inhibitor of nitric oxide, cyclooxygenase, or cytochrome P-450 monooxygenase. In contrast, catalase reduced significantly the higher concentrations of NT-702-induced vasodilation only.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:33:40 UTC 2023
Edited
by admin
on Fri Dec 15 15:33:40 UTC 2023
Record UNII
65O9DMS368
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PAROGRELIL HYDROCHLORIDE
Common Name English
3(2H)-PYRIDAZINONE, 4-BROMO-6-(3-(4-CHLOROPHENYL)PROPOXY)-5-((3-PYRIDINYLMETHYL)AMINO)-, HYDROCHLORIDE (1:1)
Systematic Name English
NM-702
Code English
Code System Code Type Description
PUBCHEM
9848253
Created by admin on Fri Dec 15 15:33:40 UTC 2023 , Edited by admin on Fri Dec 15 15:33:40 UTC 2023
PRIMARY
DRUG BANK
DB05505
Created by admin on Fri Dec 15 15:33:40 UTC 2023 , Edited by admin on Fri Dec 15 15:33:40 UTC 2023
PRIMARY
CAS
139145-84-9
Created by admin on Fri Dec 15 15:33:40 UTC 2023 , Edited by admin on Fri Dec 15 15:33:40 UTC 2023
PRIMARY
SMS_ID
100000175342
Created by admin on Fri Dec 15 15:33:40 UTC 2023 , Edited by admin on Fri Dec 15 15:33:40 UTC 2023
PRIMARY
FDA UNII
65O9DMS368
Created by admin on Fri Dec 15 15:33:40 UTC 2023 , Edited by admin on Fri Dec 15 15:33:40 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE